Autolus Therapeutics (NASDAQ:AUTL) Announces Earnings Results

Posted by Geri Gentry on May 14th, 2026

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) posted its earnings results on Thursday. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02, Zacks reports. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%.The company had revenue of $26.22 million for the quarter, compared to the consensus estimate of $26.27 million.

Here are the key takeaways from Autolus Therapeutics’ conference call:

Q1 revenue came in at $26.2 million, up sharply from $9.0 million a year ago, and management reiterated full-year 2026 revenue guidance of $120 million to $135 million.
The company reported its first positive gross margin for AUCATZYL in the quarter, supported by higher volume and manufacturing/operational improvements, with margins expected to keep improving through 2026.
Autolus said U.S. and U.K. launch momentum is building, with 73 U.S. centers active and more than 10 centers already live in the U.K.; management expects U.S. centers to exceed 80 by year-end.
The company’s real-world data continue to support obe-cel’s profile, citing no high-grade CRS, 3% high-grade ICANS, and more than 90% overall response rate, while noting patient use is expanding into older and more complex populations.
Management highlighted a broad pipeline for obe-cel, including pediatric ALL, lupus, lupus nephritis, progressive MS, and AL amyloidosis, with several data readouts expected in late 2026 through 2028.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded down $0.12 during trading on Thursday, hitting $1.59. The company had a trading volume of 2,996,422 shares, compared to its average volume of 1,748,355. The stock has a 50 day simple moving average of $1.49 and a 200 day simple moving average of $1.51. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.70. The firm has a market capitalization of $423.17 million, a P/E ratio of -1.47 and a beta of 1.93.

Wall Street Analyst Weigh In

AUTL has been the topic of a number of recent research reports. HC Wainwright increased their target price on Autolus Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Finally, Mizuho decreased their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Get Our Latest Stock Report on AUTL

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AUTL. Schroder Investment Management Group raised its stake in shares of Autolus Therapeutics by 133.7% in the third quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock worth $13,409,000 after buying an additional 4,824,763 shares during the period. Mak Capital One LLC raised its stake in Autolus Therapeutics by 15.3% during the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after purchasing an additional 3,987,727 shares during the period. Armistice Capital LLC raised its stake in Autolus Therapeutics by 30.0% during the 3rd quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after purchasing an additional 3,600,000 shares during the period. Bank of America Corp DE raised its stake in Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after purchasing an additional 1,054,458 shares during the period. Finally, Millennium Management LLC bought a new stake in Autolus Therapeutics during the 3rd quarter valued at approximately $639,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.